



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/EP2015/061909

(22) International Filing Date:

28 May 2015 (28.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/004,731 29 May 2014 (29.05.2014) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **STEELE, Keith**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **REBELATTO, Marlon C**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **BLAKE-HASKINS, John Andrew**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ROBBINS, Paul B**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **VASSELLI, James R**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **STEWART, Ross A**; MedImmune, LLC, One MedImmune Way,

Gaithersburg, Maryland 20878 (US). **IBRAHIM, Ramy**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **SHALABI, Aiman**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **WINTER, Christopher Spencer**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: ANTAGONISTS OF PDL-1 AND PD-1 FOR THE TREATMENT OF HPV-NEGATIVE CANCERS

**MEDI4736 Effect on NSCLC Tumor Size over Time
(10mg/kg)**

B Non-Small-Cell Lung Cancer




Figure 8

(57) Abstract: Provided herein are methods of treating HPV-negative tumors comprising administering an effective amount of an antagonist of the PDL-1/PD-1 interaction (e.g., an anti-PDL-1 or anti-PD-1 antibody antigen binding fragment thereof).



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with sequence listing part of description (Rule 5.2(a))*
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*